A key challenge presented by intratumoral heterogeneity is its capacity to fuel clonal evolution and the generation of therapy resistant subpopulations.[bloodjournal.org]
Thus, CLL may present in individuals with a long history of having high-count CLL/SLL MBL.[en.wikipedia.org]
Treatment [ edit ] CLL treatment focuses on controlling the disease and its symptoms rather than on an outright cure.[en.wikipedia.org]
For more than a decade, “watch and wait” has been the standard approach for patients without symptomatic disease, with frontline chemotherapy-based therapy as the conventional choice if treatment is required.[bloodjournal.org]
The distinction is important as the prognosis and therapy differ from CLL.[en.wikipedia.org]
Incorporating evolutionary concepts into schema for CLL prognosis, monitoring, and treatment The tracking of intratumoral heterogeneity over time can provide critical information on clonal dynamics, which could impact the management of patients.[bloodjournal.org]
[…] and UK NCRN CLL201 and CLL202. 36 DCFI, Dana-Farber Cancer Institute; ERIC, European Research Initiative on CLL; GCFLLC/MW-GOELAMS, French CLL Intergroup; GCLLSG, German CLL Study Group; MLL, Munich Leukemia Laboratory; SCALE, Scandinavian Lymphoma Etiology[bloodjournal.org]
[…] subtypes have a median survival of 6–8 years, while others have a median survival of 22 years (which is a normal lifespan for older patients). [ citation needed ] Telomere length has been suggested to be a valuable prognostic indicator of survival. [53] Epidemiology[en.wikipedia.org]
Thus, as an “adaptive therapy” strategy, 90 a key goal would be to maintain subclonal relationships such that the emergence of the more resistant clones is prevented.[bloodjournal.org]